Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsITGDF 72 Cash Ratio is 0.26 as of Dec. 2025, which is 57% below its 10-year median of 0.61. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $1.18 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 78.74% on this metric.
Integral Diagnostics has a Cash Ratio of 0.26. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Integral Diagnostics's Cash Ratio or its related term are showing as below:
ITGDF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.61 Max: 1.54
Current: 0.26
During the past 10 years, Integral Diagnostics's highest Cash Ratio was 1.54. The lowest was 0.21. And the median was 0.61.
ITGDF's Cash Ratio is ranked worse than 78.74% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.97
vs ITGDF: 0.26
Integral Diagnostics (OTCPK:ITGDF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Integral Diagnostics Cash Ratio Related Terms
Integral Diagnostics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ITGDF) has a Cash Ratio of 0.26 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Integral Diagnostics and its competitors. This is 57% below median its historical median of 0.61. Over the past decade, Integral Diagnostics' Cash Ratio has ranged from 0.21 to 1.54. According to the industry distribution chart, Integral Diagnostics ranks #163 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 78.7%.
Is Integral Diagnostics' Cash Ratio too high?
Integral Diagnostics' current Cash Ratio of 0.26 is 57% below median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.54. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Integral Diagnostics' value of 0.26 is 73.2% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #163 out of 207 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #163 out of 207 companies for Cash Ratio. This places Integral Diagnostics in the lower half of its industry. The industry median Cash Ratio is 0.97. Integral Diagnostics' value of 0.26 is 73.2% below this benchmark. Historically, Integral Diagnostics' own Cash Ratio has ranged from 0.21 to 1.54 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 0.97, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Cash Ratio of 0.26 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Cash Ratio is 0.26, which is 57% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.18, compared to a current price of $2.61 — trading 121.4% above its estimated fair value. The current Cash Ratio is 0.26, which is 57% below median its 10-year median of 0.61 and 73.2% below the Medical Diagnostics & Research industry median of 0.97. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current Cash Ratio is 0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 121.4% above its estimated GF Value™ of $1.18.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
Cash Ratio: 0.26 (57% below median its 10-year median of 0.61)
GF Value™: $1.18 vs. price of $2.61 (121.4% above fair value)
Industry Position: 73.2% below the Medical Diagnostics & Research median (#163 of 207)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
